17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations

17α-Alkyl-17β-oxy-estratrienes with general formula I

• 4
• in which
• Hal stands for F or Cl, and is bonded to the estratriene skeleton in 11β-position,
• R3 stands for hydrogen, C1--C4-alkyl, C1--C4-alkanoyl or a cyclic C3--C7-ether with an O atom,
• R17′stands for hydrogen, C1--C4-alkyl or C1--C4-alkanoyl,
• R17″stands for C1--C4-alkyl, C1--C4-alkyl, C1--C4-alkinyl as well as for at least partially fluorinated C1--C4-alkyl radicals,
• whereby R17′—O in 17β-position and R17″ in 17α-position are bonded to the estratriene skeleton, and
• SK stands for the grouping U—V—W—X—Y—Z—E, whereby this grouping is bonded to the estratriene skeleton via U in 7α-position,
• in which U represents either a straight-chain or branched-chain C1--C13-alkylene-, -alkenylene- or -alkinylene radical or the group A-B, whereby A is bonded to the estratriene skeleton and represents a benzylidene radical that is bonded via —CH2— to the estratriene skeleton, a phenylene radical, or a C1--C3-alkylaryl radical that is bonded via the alkyl group to the estratriene skeleton,
• and B stands for a straight-chain or branched-chain C1--C13-alkylene-,
• -alkenylene- or -alkinylene radical, and whereby A and B can also be
• connected to one another via an O atom,
• in which V further represents a CH2— or a C(O) group,
• in which W further is an N(R6)— group or an N+(O−)(R6) group or an azolidinylene ring or an azolidinylene-N-oxide ring, whereby the azolidinylene ring or azolidinylene-N-oxide ring includes at least one C atom of grouping X,
• whereby R6 further is either H or CH2—R7 or C(O)—R7, in which R7 can mean the following:
• a) hydrogen or
• b) a straight-chain or branched-chain, non-fluorinated or at least partially fluorinated C1--C14-alkyl-, -alkenyl- or -alkinyl radical, which can be hydroxylated in one or more places and can be interrupted by one to three of the heteroatoms —O—and —S—and/or the groupings —NR9—, in which R9 stands for hydrogen or a C1--C3-alkyl radical, or
• c) an unsubstituted or substituted aryl- or heteroaryl radical or
• d) an unsubstituted or substituted C3--C10-cycloalkyl radical or
• e) an unsubstituted or substituted C4--C15-cycloalkylalkyl radical or
• f) an unsubstituted or substituted C7--C20-aralkyl radical or
• g) an unsubstituted or substituted heteroaryl-C 1---C6-alkyl radical or
• h) an unsubstituted or substituted aminoalkyl radical or a biphenyl radical,
• in which X further is a straight-chain or branched-chain C1--C2-alkylene-,
• -alkenylene- or -alkinylene radical,
• in which Y further is a direct bond between X and Z or can mean the following:
• a) an SOn—R10 group, whereby n=0, 1 or 2, only if W is an N+(O−)(R6) group or an azolidinylene-N-oxide ring and not an N(R6) group or an azolidinylene ring,
• whereby R10 represents a direct bond between SOn and Z or a straight-chain or branched-chain C1--C6-alkylene-, -alkenylene- or -alkinylene radical, or
• b) the group R11 or O—R11, whereby R11 stands for
• i) a straight-chain or branched-chain C1--C5-alkylene-, -alkenylene- or -alkinylene radical or for
• ii) an unsubstituted or substituted aryl radidal or heteroaryl radical or for
• iii) an unsubstituted or substituted C3--C10-cycloalkyl radical or for
• iv) an unsubstituted or substituted C4--C15-cycloalkylalkyl radical or for
• v) an unsubstituted or substituted C7--C20-aralkyl radical or for
• vi) an unsubstituted or substituted heteroaryl-C1---C6-alkyl radical, or
• c) the grouping CH═CF or
• d) the grouping HN—C(O)—NH—R12, whereby R12 stands for an unsubstituted or substituted arylene radical, and whereby R 12 is bonded to Z, and in which Z further is a direct bond between Y and E or a straight-chain or branched-chain C1--C9-alkylene-, -alkenylene- or -alkinylene radical, which can be partially or completely fluorinated, and in which E further is a CF3 group or an at least partially fluorinated aryl group,
• whereby pharmacologically compatible acid addition salts as well as esters are also included.